Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,070 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival.
Carson WE 3rd, Unger JM, Sosman JA, Flaherty LE, Tuthill RJ, Porter MJ, Thompson JA, Kempf RA, Othus M, Ribas A, Sondak VK. Carson WE 3rd, et al. Among authors: thompson ja. Cancer Immunol Res. 2014 Oct;2(10):981-7. doi: 10.1158/2326-6066.CIR-14-0052. Epub 2014 Jul 3. Cancer Immunol Res. 2014. PMID: 24994597 Free PMC article. Clinical Trial.
Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group.
Sondak VK, Liu PY, Tuthill RJ, Kempf RA, Unger JM, Sosman JA, Thompson JA, Weiss GR, Redman BG, Jakowatz JG, Noyes RD, Flaherty LE. Sondak VK, et al. Among authors: thompson ja. J Clin Oncol. 2002 Apr 15;20(8):2058-66. doi: 10.1200/JCO.2002.08.071. J Clin Oncol. 2002. PMID: 11956266 Clinical Trial.
Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome.
Sosman JA, Unger JM, Liu PY, Flaherty LE, Park MS, Kempf RA, Thompson JA, Terasaki PI, Sondak VK; Southwest Oncology Group. Sosman JA, et al. Among authors: thompson ja. J Clin Oncol. 2002 Apr 15;20(8):2067-75. doi: 10.1200/JCO.2002.08.072. J Clin Oncol. 2002. PMID: 11956267 Clinical Trial.
Total body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood stem-cell transplantation followed by randomization to therapy with interleukin-2 versus observation for patients with non-Hodgkin lymphoma: results of a phase 3 randomized trial by the Southwest Oncology Group (SWOG 9438).
Thompson JA, Fisher RI, Leblanc M, Forman SJ, Press OW, Unger JM, Nademanee AP, Stiff PJ, Petersdorf SH, Fefer A. Thompson JA, et al. Blood. 2008 Apr 15;111(8):4048-54. doi: 10.1182/blood-2007-09-111708. Epub 2008 Feb 6. Blood. 2008. PMID: 18256325 Free PMC article. Clinical Trial.
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.
Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA. Motzer RJ, et al. Among authors: thompson ja. J Clin Oncol. 2009 Aug 1;27(22):3584-90. doi: 10.1200/JCO.2008.20.1293. Epub 2009 Jun 1. J Clin Oncol. 2009. PMID: 19487381 Free PMC article. Corrected and republished. Clinical Trial.
Treatment of metastatic melanoma: an overview.
Bhatia S, Tykodi SS, Thompson JA. Bhatia S, et al. Among authors: thompson ja. Oncology (Williston Park). 2009 May;23(6):488-96. Oncology (Williston Park). 2009. PMID: 19544689 Free PMC article. Review.
1,070 results